STAT3 signaling in CAR T cell products has been associated with improved responses in chronic lymphocytic leukemia patients (80) and modulation of STAT3 signaling has been used to improve CAR T cells in other preclinical models (29). This evidence concerns the gene STAT3 and B-cell chronic lymphocytic leukemia.